Arcataur Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Arcataur Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$723K	Buy	1,456 +22	+2%	+$9.75K	0.18%	49
2026 Q1	$640K	Hold	1,434	–	–	0.18%	54
2025 Q4	$650K	Sell	1,434 -5	-0.3%	-$2.15K	0.19%	54
2025 Q3	$564K	Sell	1,439 -57	-4%	-$23.8K	0.17%	56
2025 Q2	$666K	Hold	1,496	–	–	0.21%	46
2025 Q1	$725K	Sell	1,496 -158	-10%	-$73.6K	0.25%	43
2024 Q4	$666K	Hold	1,654	–	–	0.22%	43
2024 Q3	$769K	Hold	1,654	–	–	0.26%	42
2024 Q2	$775K	Sell	1,654 -6	-0.4%	-$2.6K	0.28%	38
2024 Q1	$694K	Sell	1,660 -615	-27%	-$260K	0.25%	41
2023 Q4	$926K	Sell	2,275 -13	-0.6%	-$4.8K	0.35%	29
2023 Q3	$796K	Hold	2,288	–	–	0.33%	29
2023 Q2	$805K	Buy	+2,288	New	+$771K	0.33%	30

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Arcataur Capital Management's VRTX Position: Q2 2026 in Review

Arcataur Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, buying an estimated $9.75K and bringing the position to 1,456 shares worth $723K. The position accounts for 0.18% of the portfolio, ranked #49.

Arcataur Capital Management first reported a position in VRTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $926K in Q4 2023. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Arcataur Capital Management held 1,456 shares of Vertex Pharmaceuticals worth $723K as of Q2 2026.
Arcataur Capital Management bought 22 Vertex Pharmaceuticals shares in Q2 2026, an estimated $9.75K.
Vertex Pharmaceuticals made up 0.18% of Arcataur Capital Management's portfolio in Q2 2026, its #49 holding.
Arcataur Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Arcataur Capital Management's Vertex Pharmaceuticals position peaked at $926K in Q4 2023.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Arcataur Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.